Trial Profile
Sorafenib in the treatment of AML patients with FLT3-ITD mutation: a cohort study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Nov 2016
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 25 Jul 2014 New trial record